SCHEMBL30152880

SCHEMBL30152880

Cn1cnnc1-c1ccccc1-c1cc(-c2nc3cc(CN4CCC5(CC5)C4)cc(C(F)(F)F)c3o2)nc(C2CC2)c1

nearest known ligand 0.38

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 18/20 0.38
▸ PDCD1 Q15116 2/20 0.32
▸ CD274 Q9NZQ7 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24820257 1.00 CBLB (0.38) CBLBPDCD1CD274
SCHEMBL29189932 0.87 CBLB (0.41) CBLBPDCD1CD274
SCHEMBL30152755 0.87 CBLB (0.41) CBLBPDCD1CD274
SCHEMBL30152715 0.87 CBLB (0.41) CBLBPDCD1CD274
SCHEMBL24820254 0.87 CBLB (0.41) CBLBPDCD1CD274
SCHEMBL24820255 0.87 CBLB (0.41) CBLBPDCD1CD274
SCHEMBL24819962 0.86 CBLB (0.38) CBLB
SCHEMBL30152648 0.86 CBLB (0.38) CBLB
SCHEMBL24818547 0.82 CBLB (0.41) CBLB
SCHEMBL30153087 0.82 CBLB (0.41) CBLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. 2025-05-22 — — US disclosed
EP-4359381-A1 CBL-B MODULATORS AND USES THEREOF Nimbus Clio, Inc. (US) 2024-05-01 — — EP disclosed
CN-117858865-A CBL-B modulators and uses thereof 林伯士克莱奥公司 2024-04-09 — — CN disclosed
WO-2022272248-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2022-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC CBLB 1/4885PDCD1 1429/4885CD274 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback